comparemela.com

Lily Zhou News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Degron, Takeda bind $1 2B deal for molecular glue degraders

Shanghai- and San Diego-based Degron Therapeutics Inc. secured a potential $1.2 billion deal with Tokyo-headquartered Takeda Pharmaceutical Co. Ltd. May 23 for a multitarget collaboration and exclusive licensing agreement for molecular glue degraders.

Celebrate Lunar New Year 2024 in San Diego County with these events

vimarsana © 2020. All Rights Reserved.